Beyond Big Tech: 10 Under-the-Radar US Stocks Making Moves This WeekGlobal Report·Jul 9 at 09:02 PMCELG.RT0.00%RZLV+4.02%
Capital Rotates into Niche Tech and Healthcare RestructuringsGlobal Report·Jul 9 at 05:03 AMCVBF-0.24%FHTX-0.53%
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 | FHTX Stock NewsStockTitan·Jun 4 at 10:00 PMFHTX-0.53%
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga_article·May 15 at 04:06 PMARAY+8.96%SNSE0.00%
Foghorn Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 3.267 MEarnings Watch·May 7 at 06:05 AMFHTX-0.53%
Foghorn Therapeutics (FHTX) Receives a Buy from Stifel NicolausTip Ranks·Apr 27 at 07:45 AMFHTX-0.53%
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACRTip Ranks·Apr 21 at 03:53 PMFHTX-0.53%LLY-3.81%
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingUnusual Whales·Apr 9 at 06:01 AMXBI+0.91%FHTX-0.53%
Fennec Pharmaceuticals Signals Costly Push Toward GrowthTip Ranks·Mar 27 at 07:23 PMIXJ-1.68%BBH-2.11%
Foghorn Narrows Losses, Strengthens Cash Runway, Advances Cancer Pipelinenasdaq·Mar 12 at 02:00 AMFHTX-0.53%
Foghorn Advances FHD-909 Trial and Strengthens Financial PositionTip Ranks·Mar 11 at 08:29 PMFHTX-0.53%
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic OutlookUnusual Whales·Mar 11 at 03:11 PMIBBQ-0.95%FBT-0.46%
